Oncofusion

start / graph / ana-q199-dot1l-carries-52-in-gene-genome-wide-significant-snps-at-the-97-8th-length-matched-percentile-led-by-height-and-blood-pressure-traits

Analysisspeculative confidence 1 of 5: Our own inference or analogy. Not shown to be true.

DOT1L carries 52 in-gene genome-wide-significant SNPs at the 97.8th length-matched percentile, led by height, pulse pressure and blood-pressure traits - a speculative cardiovascular lead for DOT1L-directed drugs

Inherited variation in DOT1L, the enzyme several leukaemia drugs target, is linked to height and blood pressure. That is a faint hint, not a warning, that blocking it might touch the circulation.

The same thing, for a scientist

DOT1L: 52 distinct in-gene genome-wide-significant SNPs (143 rows, 69 traits), 97.8th percentile among 3216 genes of similar length; top traits Height (15); Pulse pressure (9); Hip circumference adjusted for BMI (9); Systolic blood pressure (9); Waist-to-hip ratio adjusted for BMI (6).

Go deeper
How little this is

Height and blood pressure are among the most polygenic human traits, so many genes collect hits for them. The length-matched percentile controls for gene size but not for trait polygenicity, and the Catalog maps by proximity. Direction of effect is unknown, and common regulatory variation is not pharmacological inhibition. This is a lead to check against trial adverse-event tables, nothing more.

Facts and figures
scriptanalyses/q199-germline-genetics-of-the-fusion-pathway/run.py
top traits
Hematocrit5.000Hematocrit: 5Waist-to-hip ratio adjust…6.000Waist-to-hip ratio adjusted for BMI: 6Pulse pressure9.000Pulse pressure: 9Hip circumference adjuste…9.000Hip circumference adjusted for BMI: 9Systolic blood pressure9.000Systolic blood pressure: 9Height15.0Height: 15
dot1l
{
  "gene": "DOT1L",
  "len_kb": 68.6,
  "snps": 52,
  "rows": 143,
  "traits": 69,
  "n_length_matched": 3216,
  "pct_length_matched": 97.8,
  "context": {
    "intron_variant": 127,
    "3_prime_UTR_variant": 12
  }
}
top traits — the numbers behind the chart
{
  "Height": 15,
  "Pulse pressure": 9,
  "Hip circumference adjusted for BMI": 9,
  "Systolic blood pressure": 9,
  "Waist-to-hip ratio adjusted for BMI": 6,
  "Hematocrit": 5
}
How this could bite us back
  • If DOT1L inhibition does shift vascular traits, infants on anthracycline-containing backbones are where an additive cardiovascular effect would matter. Nothing here shows that it does.
Still open
  1. Do the posted adverse-event tables of the pinometostat trials show hypertension or other haemodynamic events, and were infants on anthracycline-containing regimens separately examined?
Every source behind this entry (1)
  1. E1weak confidence 2 of 5: Preliminary, small, indirect, or not yet peer reviewed.database

    DOT1L has 52 distinct genome-wide-significant in-gene SNPs in the GWAS Catalog (97.8th percentile of genes of similar length), most frequently for height (15 rows), pulse pressure (9), hip circumference adjusted for BMI (9) and systolic blood pressure (9).

    What this evidence cannot show

    Row counts per trait are from the in-gene set; the same SNP can appear under several correlated blood-pressure traits.

    Evidence that argues against this (1)
    • Blood pressure and height are extremely polygenic, so many genes show associations; no trait-matched null was run. A hit says the locus is associated with the trait, not that inhibiting the enzyme changes it, and the direction is unknown. No DOT1L-inhibitor trial adverse-event table was examined. GWAS Catalog 2026
Connected to